Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Equity Ratio (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Equity Ratio for 4 consecutive years, with 0.77 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio rose 61.86% to 0.77 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.77, a 61.86% increase, with the full-year FY2024 number at 0.4, down 32.36% from a year prior.
  • Equity Ratio was 0.77 for Q3 2025 at bioAffinity Technologies, up from 0.45 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q1 2023 to a low of 0.45 in Q2 2025.
  • A 4-year average of 0.58 and a median of 0.65 in 2024 define the central range for Equity Ratio.
  • Biggest YoY gain for Equity Ratio was 61.86% in 2025; the steepest drop was 187.17% in 2025.
  • bioAffinity Technologies' Equity Ratio stood at 0.91 in 2022, then tumbled by 34.86% to 0.59 in 2023, then tumbled by 32.36% to 0.4 in 2024, then soared by 93.0% to 0.77 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Equity Ratio are 0.77 (Q3 2025), 0.45 (Q2 2025), and 0.26 (Q1 2025).